Uterine leiomyosarcoma (LMS) is a highly metastatic smooth muscle neoplasm for which calponin h1 is suspected to have a biological role as a tumor-suppressor. We earlier reported that LMP2-null mice spontaneously develop uterine LMS through malignant transformation of the myometrium, thus implicating this protein as an anti-tumorigenic candidate as well. In the present study, we show that LMP2 may negatively regulate LMS independently of its role in the proteasome. Moreover, several lines of evidence indicate that although calponin h1 does not directly influence tumorigenesis, it clearly affects LMP2-induced cellular morphological changes. Modulation of LMP2 may lead to new therapeutic approaches in human uterine LMS. (104 words)
Introduction
Smooth muscle tumors (SMTs) are commonly divided into benign leiomyoma (LMA) and malignant leiomyosarcoma (LMS) based on cytological atypia, mitotic activity, and other criteria.
Uterine LMS is a rare gynecologic malignancy in the female genital tract, with an estimated annual incidence of 0.64 per 100,000 women [1] . LMS accounts for approximately one-third of uterine sarcomas, of which 53% are confined to the uterus [2] [3] [4] [5] . Gynecological tumors are strongly promoted by female hormones. The rate of hormone receptor expression is reported to be significantly lower in human uterine LMS than in normal myometrium, but these low receptor levels were found to correlate neither with the promotion of initial disease development, nor with the overall survival of patients with uterine LMS.
Although uterine LMS is sensitive to certain types of chemotherapy with gemcitabine or docetaxel, it is resistant to hormone therapy and radiotherapy, and thus surgical intervention is virtually the only means of treatment at present [6] [7] [8] . It should be noted that when adjusted for stage and mitotic count, LMS has a significantly worse prognosis than carcinosarcoma; the 5-year survival rate for patients with uterine LMS is 15%-25%. The development of effective adjuvant treatments is expected to improve the outcome of this disease through the use of emerging molecular targeting therapies [4, 5, [9] [10] [11] . Determining the malignant potential of smooth muscle neoplasms also represents a significant diagnostic conundrum with important therapeutic ramifications. However, the genetic changes underlying the neoplastic transformation of uterine smooth muscle cells (SMCs) have not been fully characterized.
The ubiquitin-proteasome degradation pathway is essential for many cellular processes, including cell cycle and regulation of gene expression. Abnormal expression of low molecular weight protein (LMP)2, LMP7, and LMP10(MECL-1) subunits is therefore believed to contribute to the initiation and development of disorders. A recent study revealed a unique role for LMP7 in controlling pathogenic immune responses and provided a therapeutic rationale for targeting LMP7 in autoimmune disorders, especially rheumatoid arthritis [12] . It is also noteworthy that mice with a targeted disruption of LMP2 exhibited defects in tissue-and substrate-dependent proteasomal function, and that female LMP2-null mice spontaneously developed uterine LMS with a disease prevalence of 40% by 14 months of age [13, 14] . Furthermore, LMP2 expression was markedly down-regulated in human uterine LMS tissues in comparison with both LMA and normal myometrium. This defective LMP2 expression was attributable to somatic mutations in the catalytic region of JAK1 in tumor tissues from patients with uterine LMS [15] , and so defective LMP2 expression is likely to be one of the risk factors in the development of human uterine LMS as it is in LMP2-null mice [14, 15] . In addition, recent reports have shown an association between malignant transformation of the myometrium and reduced expression of calponin h1, which is specifically expressed in smooth muscle and binds calmodulin, actin, and tropomyosin [16, 17] . Calponin h1 reportedly inhibits the ATPase activity of myosin and may play a role in smooth muscle contraction [18, 19] . Although calponin h1 may function as a tumor-suppressor in uterine LMS, calponin h1-null mice do not exhibit uterine LMS. The biological characterization of human uterine LMS remains incomplete [16, 17] .
In the present study, we investigated the molecular mechanism behind the tumorigenesis of human uterine LMS involving defective LMP2 expression. Biological and histological findings showed that while calponin h1 expression was clearly induced by LMP2, defective calponin h1 expression contributed to abnormal cell morphology, but to not cell proliferation, which directly correlated to tumor progression. Thus, LMP2 expression appeared to be responsible for the calponin h1-mediated morphological phenotypes in human uterine LMS cells in an anti-oncogenic manner.
Continued improvement of our knowledge of the molecular biology of uterine LMS may ultimately lead to novel diagnoses and therapies and improved outcome. (612 words) 4 
Materials and Methods

Tissue Collection.
A total of 51 patients aged between 32 and 83 years who were diagnosed as having smooth muscle tumors of the uterus were selected from pathological files. Serial sections were obtained from at least 2 tissue blocks from each patient for hematoxylin and eosin staining and immunostaining. All tissues were used with the approval of the Ethical Committee of Shinshu University after obtaining written consent from each patient.
Western Blotting.
To detect the expression of LMP2, LMP7, cyclin B, calponin h1, SRF, and β-actin, whole cell lysates, nuclear extracts, or cytosolic extracts were resolved by 10% SDS-PAGE, and immunoblotting was performed using appropriate antibodies by standard procedures. Fig. 1 ). One LMS sample retained the expression of LMP2
( Supplementary Fig. 1 ). Of the 32 patients with uterine LMS examined, 31 were negative for calponin h1, and 1 was partially positive (Supplementary Fig. 1 ). All lymph nodes were negative for LMS metastases, and IHC showed positivity for Ki-67 and negativity for LMP2 and calponin h1. In both Western blotting and RT-PCR experiments, LMP2 and calponin h1 were expressed in normal myometrium but not in human uterine LMS, which were strongly supportive of the IHC findings.
Although our research group previously demonstrated that the abnormal expression of the ovarian steroid receptors, TP53, and Ki-67, and mutations of TP53 were frequently associated with uterine LMS, defective LMP2 and calponin h1 expression appeared to be more characteristic of uterine LMS in our cohort (Supplementary Table 1 ).
The defective LMP2 expression was attributable to somatic mutations in the catalytic region of JAK1 in tumor tissues from our patients with uterine LMS [15] (Supplementary Table 1 ). Although cell proliferation has been demonstrated to be strongly inhibited by IFN-γ-induced JAK1 kinase activation [20] , it is difficult to demonstrate tumorigenicity in JAK1-null mice because they die perinatally [21] . Therefore, the differential responsiveness to genetically modified stable LMP2 expression of the SKN human uterine LMS cell line was investigated to determine whether reintroducing LMP2 into a LMS cell line would affect its tumorigenic properties for development of uterine LMS and if the observed effect was due to the immunoproteosomal function of the protein.
SKN cells were transfected with pCEM9, pCEM9-LMP2wt, or pCEM9-LMP2K33A, which has no effect on immunoproteasome function due to non-incorporation into the 20S proteasome [22] ( Supplementary Fig. 2 ), and selected in medium containing G418. The efficiency of neo-marker transfer of these three plasmids was comparable (Supplementary Table 2 ). However, in the case of pCEM9-LMP2wt, approximately 78% (LMP2wt) or 76% (LMP2K33A) of the total G418-resistant colonies were relatively compact and appeared dark when observed under a phase-contrast microscope after 6-7 days of selection (Supplementary Table 2 The association between reduced expression of calponin h1 and malignant transformation of the myometrium suggests that re-expression of human calponin h1 can suppress cell proliferation and tumorigenicity in uterine LMS cells [16, 17] . Calponin h1 was highly expressed in myometrium and leiomyoma of the uterus, but was very poorly expressed or negative in LMS [16, 17] ( Supplementary   Fig. 1 , Table 1 ). However, unlike mice lacking LMP2, calponin h1-null mice do not exhibit uterine LMS [14, 15] . To examine the biological connection between LMP2 and calponin h1, we analyzed the expression pattern of calponin h1 in the SKN-CEM9 clone (2 clones), SKN-LMP2wt (F type)
clone (8 clones), and SKN-LMP2K33A (F type) clone (4 clones) ( Supplementary Fig. 3 ).
Unexpectedly, our results revealed that calponin h1 was markedly expressed in both SKN-LMP2wt
(F type) and SKN-LMP2K33A (F type) clones (Fig. 1B,C, Supplementary Fig. 4 , Table 3 ).
Calponin h1 expression depended on the presence of LMP2, suggesting that LMP2 may involve the function of calponin h1 in tumor suppression of human uterine LMS. In reporter assays, the calponin h1 promoter was markedly activated in SKN-LMP2 (F type), #121, and #122 clones, but not in SKN-CEM9#2, which was strongly supportive of the RT-PCR and Western blotting assays (Fig. 1) . Recent papers have demonstrated serum response factor (SRF)-dependent regulation of the human smooth muscle calponin h1 gene [23, 24] . Here, mutation of SRF binding sites abolished the ability of stable LMP2 expression to induce SRF gene expression in SKN-LMP2wt (F-type), #121, and #122 clones (Fig. 1D) . RT-PCR and Western blotting experiments showed that stable expression of LMP2 induced SRF expression, which may account for the activation of calponin h1 gene expression in SKN-LMP2wt (F-type) clones (Fig. 1, Supplementary Fig. 4 ).
To demonstrate the functional significance of calponin h1 on LMP2-induced differential cellular phenotypes, additional experiments were performed on cell morphology, cell cycle, and tumorigenesis of human uterine LMS. The SKN cell line was co-transfected with pCEM9-LMP2wt plus calponin h1shRNA or Scr.shRNA (negative-control vector) (Santa Cruz Biotechnology Inc.
9 CA, USA) and then selected in medium containing G418. The efficiency of neo-marker transfer with combinations of these plasmids was comparable (Fig. 2) . However, in SKN-LMP2/Scr.shRNA colonies, approximately 96.4% of G418-resistant cells were relatively compact and appeared dark when observed under a phase-contrast microscope after 6-7 days of selection (Supplementary Table   4 ). After 2 to 3 weeks, when most of the colonies outgrew and detached from the substrate, colonies consisting of SKN-LMP2wt/Scr.shRNA flatrevertant (F type) cells (4 clones) were found at frequencies of approximately 59.1% of the total number of G418-resistant colonies initially observed (Fig. 2) . Furthermore, colonies of P/T type or T type morphology were observed in cultures co-transfected with LMP2wt plus calponin h1shRNA (4 clones), which specifically prevents calponin h1 expression (Fig. 2 , Table 2 , Supplementary Fig. 5 ). No colonies with morphological changes were observed in the SKN cultures co-transfected with CEM9 plus calponin h1shRNA or Scr.shRNA (Fig. 2, Table 2 , Supplementary Fig. 5 ). Western blotting and RT-PCR analysis demonstrated that although calponin h1 was clearly detected in the SKN-LMP2wt/Scr.shRNA colony (4 clones), calponin h1shRNA markedly prevented calponin h1 expression in the SKN-LMP2wt/calponin h1shRNA colony (4 clones) (Fig. 2 , Table 2 , Supplementary Fig. 4 ). These findings suggest that LMP2-induced cellular morphological phenotypes involved the biological function of calponin h1. We confirmed that the morphological change was due to the impaired expression of calponin h1 by using shRNAs against different calponin h1 sequences ( Supplementary Fig. 6 ).
We next isolated and expanded representative colonies of each cell type and analyzed their growth properties. The growth rate of the SKN-LMP2wt/calponin h1shRNA (T type) colony (4 clones), measured as population doubling time (PDT), was slightly higher than that of the SKN-LMP2wt/Scr.shRNA colony (F type) (4 clones) (Fig. 2 , Table 2 ). We also analyzed their tumorigenic properties as well as the occurrence and expression of LMP2 and calponin h1. The efficiency of colony formation and size of the clones in soft agar were not significantly reduced in the SKN-LMP2wt/calponin h1shRNA (T type) colony (4 clones) as compared with those of the SKN-LMP2wt/Scr.shRNA (F type) colony (4 clones) ( Table 3 ). The present experiments suggest that the expression of calponin h1 might affect cell morphology, but not suppression of tumorigenicity in the LMP2-induced differentiation of cellular phenotype.
Discussion
Recent molecular targeting therapies against tumors have achieved remarkable results. To improve the prognosis of human uterine LMS, studies are being performed to identify the roles of key pro-and anti-oncogenic factors that have important functions in tumor pathogenesis and may serve as molecular targets for treatment. For this purpose, several research groups have shown that cell cycle regulatory factors and known pro-oncogenic factors, such as the brain-specific polypeptide PEP-19 and c-kit, may be associated with the pathogenesis of human uterine LMS [25] [26] [27] [28] . LMP2-null mice are reportedly prone to the spontaneous development of uterine LMS [14] .
In the present study, histopathological experiments demonstrated a high correlation between a loss of LMP2 and calponin h1 and the malignancy of uterine tumors developing in the myometrium. It is interesting that only LMP2-null mice spontaneously developed uterine LMS, especially since the individual expression of LMP2, LMP7, and LMP10/MECL-1 subunits has been reported to contribute to the initiation and development of several disorders [12, 14, 15] .
Calponin h1 most likely exerts its biologic effects through interactions with other cellular molecules that transduce signals from outside the cell. Calponin h1 can promote actin filament stability in vitro by inhibiting depolymerization [29] . Cell attachment and spreading are essential for cells to traverse through the G 1 phase of the cell cycle [30] . The present observations on cell morphology following LMP2-induced calponin h1 expression suggest that calponin h1 may inhibit the signaling pathways concerned with the control of cellular morphology, including cell attachment, cell shape, and spreading. The calponin h1 gene is expressed in resting aortic SMCs, but its expression rapidly decreases when growth-arrested cells re-enter the G 1 phase and proliferate.
Thus, this protein inhibits proliferation in SMCs and fibroblasts [31, 32] . Our findings show that calponin h1 expression under stable LMP2 expression affects cellular morphology, but does not markedly suppress cell proliferation and tumorigenicity in LMS cells.
The molecular mechanisms by which calponin h1 gene-inducing SRF expression is induced by single-unit LMP2 are poorly understood in LMS. The functionally inactivated K33A mutant of LMP2 has the same morphology in vitro as the wt transfectant, suggesting that LMP2 acts not only through its role in proteasomes, but also as a single subunit. The relative amounts of LMP2 and LMP7 vary significantly among tissues and cell lines in mice and humans [33] , and LMP2 levels in proteasomes show greater variation among tissues than do those of LMP7 [33] . Proteasome subunits that are not incorporated into complexes are believed to individually mediate gene transcriptional activation together with other co-factors [34] . For instance, LMP2 is also reportedly required for estrogen receptor-mediated gene transcription as well as for estrogen-stimulated cell cycle progression [35] . Other reports have demonstrated the nuclear localization of single-unit LMP2 in various mammalian tissues and cell types [33, 36] , where single-unit LMP2 may regulate calponin h1 
Acknowledgments
We sincerely appreciate the donation of LMP2-null breeding mice and scientific cooperation of 
Appendix A. Supplementary data
Supplementary data associated with this article can be found in the online version of this paper at doi: Table S4 . Table 1 and Table S5 . The experiments were repeated three times with similar results.
